40069-10-1Relevant articles and documents
LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE
-
Paragraph 086, (2016/06/01)
Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase Bl (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of
Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores
Trstenjak, Uro?,Ila?, Janez,Kikelj, Danijel
supporting information, p. 302 - 313 (2013/07/27)
Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa an
Design and synthesis of boron containing potential pan-RAR inverse agonists
Das, Bhaskar C.,Tang, Xiang-Ying,Evans, Todd
body text, p. 1316 - 1318 (2012/04/04)
We designed and successfully synthesized the compounds 5 and 8 as potential pan-RAR (retinoic acid receptor) agonists. These two compounds were designed based on an existing pan-RAR agonist (BMS493). We synthesized compound 5, in which the carboxylic acid
Rapid catalyst identification for the synthesis of the pyrimidinone core of HIV integrase inhibitors
Bellomo, Ana,Celebi-Olcum, Nihan,Bu, Xiaodong,Rivera, Nelo,Ruck, Rebecca T.,Welch, Christopher J.,Houk, Kendall N.,Dreher, Spencer D.
supporting information; body text, p. 6912 - 6915 (2012/10/08)
A microscale chemistry improvement engine: A pre-dosed microscale high-throughput experimentation additives platform enables rapid, serendipitous reaction improvement. This platform allowed one chemist to set up 475 experiments and analyze the results using MISER chromatography in a single day, thus resulting in two high-quality catalytic systems for the construction of the title compound 1. Support for a single-electron transfer mechanism was obtained. Copyright
AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
-
Page/Page column 16-17, (2010/04/30)
The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.
THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1
-
Page/Page column 15, (2010/11/03)
The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).
AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS
-
Page/Page column 41, (2008/12/07)
The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.